Adverse events: infection · adults with chronic pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: other · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain intensity (number of people with ≥ 50% improvement) · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation for RSV infection · children (0 to 24 months)
Palivizumab leads to lower hospitalisation due to RSV infection compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
All‐cause mortality · children (0 to 24 months)
Palivizumab showed no clear difference in mortality compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Adverse events · children (0 to 24 months)
Palivizumab showed no clear difference in adverse events compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Hospitalisation due to respiratory‐related illness · children (0 to 24 months)
Palivizumab probably leads to lower hospitalisation due to respiratory‐related illness compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
RSV infection · children (0 to 24 months)
Palivizumab may leads to lower RSV infection compared with placebo, no intervention or standard care (low certainty).
1 finding from 1 review
Number of wheezing days · children (0 to 24 months)
Palivizumab leads to lower number of wheezing days compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19
1 finding from 1 review
Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab may leads to lower admission to hospital or death compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found